Management of dyslipidemia in adults with diabetes

• Published in: Diabetes care Vol. 21; no. 1; pp. 160 - 178
• Main Author: Haffner, S.M. (University of Texas Health Science Center, San Antonio, TX.)
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.01.1998
• Subjects: Adult; Associated diseases and complications; Atherosclerosis; Biological and medical sciences; BLOOD LIPIDS; CARDIOPATHIE; Cardiovascular disease; CLINICAL TRIALS; Clinical Trials as Topic; CONTROL DE ENFERMEDADES; CONTROLE DE MALADIES; Coronary Disease - epidemiology; Coronary Disease - prevention & control; DIABETE; DIABETES; Diabetes Complications; diabetes mellitus; Diabetes Mellitus - therapy; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 2 - complications; Diabetes. Impaired glucose tolerance; Diabetic Angiopathies - epidemiology; Diabetic Angiopathies - prevention & control; DISEASE CONTROL; DISEASE PREVENTION; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; ENFERMEDADES CARDIACAS; ENSAYOS CLINICOS; ESSAI CLINIQUE; Heart; HEART DISEASES; Hemoglobin; HEMOLIPIDOS; HIPERLIPIDEMIA; Humans; Hyperglycemia; HYPERLIPIDAEMIA; hyperlipidemia; Hyperlipidemias - complications; Hyperlipidemias - epidemiology; Hyperlipidemias - therapy; HYPERLIPIDEMIE; Hypolipidemic Agents - therapeutic use; INSULIN RESISTANCE; Ischemia; LIPIDE SANGUIN; Medical sciences; Metabolic disorders; Middle age; Observational studies; PATIENTS; Prediabetic State - complications; Risk factors; United States; North America; America; Endocrinopathy; Human; Prevalence; Pathophysiology; Diabetes mellitus; Treatment efficiency; Cardiovascular disease; Metabolic diseases; Lipids; Coronary heart disease; Epidemiology; Prevention; Association; Diet therapy; Etiology; Risk factor; Dyslipemia; Comparative study; Life habit
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/diacare.21.1.160

Management of dyslipidemia in adults with diabetes. S M Haffner Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7873, USA. Abstract Subjects with diabetes have a greatly increased risk of CHD, which is only partially related to their elevated glucose. Other factors such as insulin resistance and dyslipidemia are likely to be important. The type of dyslipidemia that is most characteristic of type 2 diabetic subjects is elevated triglycerides and decreased HDL cholesterol levels, although all lipoproteins have compositional abnormalities. Surprisingly few good prospective studies of lipoprotein levels in relation to CHD have been done in diabetic subjects. Available studies suggest that low HDL cholesterol may be the most important risk factor for CHD in observational studies. In studies in which total cholesterol and triglyceride were done, cholesterol and triglycerides were risk factors for CHD, although triglycerides were often a stronger predictor. However, the strength of triglyceride as a risk factor for CHD may depend partially on its association with other variables (e.g., hypertension, plasminogen activator inhibitor 1 [PAI-1], etc.). In clinical trials in diabetic subjects, LDL reduction with statins has led to significant reductions in CHD incidence. In addition, overall mortality was reduced with statin therapy, although the results were not statistically significant. Gemfibrozil has led to reductions in CHD incidence in diabetic subjects, although the results were not statistically significant perhaps because of low sample size. Regarding lipoproteins and CHD risk in diabetic patients, the very positive results of statin trials point to LDL cholesterol being more important than previous realized. Apparently, having a borderline high LDL cholesterol (between 130 and 160 mg/dl) in a diabetic patient is equivalent to a much higher LDL cholesterol in terms of CHD risk for a nondiabetic subject. Therefore, the primary target of therapy in diabetic patients is lowering LDL cholesterol (or possibly, non-HDL cholesterol). Statins are the preferred pharmacological agent in this situation. Once LDL cholesterol levels have been lowered, attention can be given to treatment of residual hypertriglyceridemia and low HDL. The goal here is weight reduction and increased exercise. However, for selected patients, combining a fibric acid (or low-dose nicotinic acid) with a statin also can be considered. Reduction of LDL levels should take priority over reduction of triglycerides in combined hyperlipidemia because of the proven safety of the statin class of drugs as well as greater reduction in CHD incidence.